Northside Hospital, Inc.

northside.com

Total trials

26

Active

8

Phase 3

0

Total enrollment

783

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 13 of 13 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Cyclophosphamide7
Fludarabine5
tacrolimus5
Rituximab4
methotrexate3
Sargramostim1
Blinatumomab1
Belumosudil1
Mycofenolate mofetil1
Rabbit ATG1
Decitabine2
Venetoclax2
Axatilimab1

Next readouts

  • 2026-08-31
  • 2026-09-18
  • 2026-11-01
  • 2026-12-31
  • 2027-06-30
  • 2027-08-31
  • 2029-08-01

Top conditions

  • Myelodysplastic Syndromes5
  • Multiple Myeloma4
  • Leukemia4
  • Lymphoma4
  • Myelodysplastic Syndrome3
  • Acute Myeloid Leukemia3
  • Acute Leukemia2
  • Chronic Leukemia2

Frequently asked questions about Northside Hospital, Inc.

How many clinical trials does Northside Hospital, Inc. have on ClinicalTrials.gov?
Northside Hospital, Inc. is listed as the lead sponsor on 26 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
How many of Northside Hospital, Inc.'s trials are in Phase 3?
0 of Northside Hospital, Inc.'s trials are in Phase 3, spread across 13 active drug programs.
What therapeutic areas does Northside Hospital, Inc. focus on?
Northside Hospital, Inc.'s most-studied conditions on ClinicalTrials.gov are Myelodysplastic Syndromes, Multiple Myeloma, Leukemia, Lymphoma, Myelodysplastic Syndrome.
When are Northside Hospital, Inc.'s next clinical trial readouts?
Northside Hospital, Inc. has 7 upcoming primary-completion readouts tracked here; the soonest is “CAR T-cell Therapy in Patients With Renal Dysfunction”, expected around 2026-08-31.